CTSC and chronic obstructive pulmonary disease: Other agents such as the DPP-1 inhibitor brensocatib have shown clearer attenuating effects upon sputum neutrophil activity with associated clinical efficacy in terms of exacerbation prevention in bronchiectasis33 but these approaches have not yet been tested in COPD.